Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medical Affairs Pharma

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

- PMLiVE

Pfizer closes on Xeljanz filing in ulcerative colitis

Latest positive data could help the slow-growing drug meet blockbuster sales expectations

Eli Lilly HQ

Lilly and Boehringer combine breast cancer drugs in trial

Firms anticipate together the two drugs will offer a “more complete pathway interference”

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

Bristol-Myers Squibb (BMS) building

SMC gives green light for BMS’ Opdivo

Scotland will be first UK country to access the drug after NICE refusal

- PMLiVE

Pfizer warns against price-cutting after NICE backs Bosulif

Cancer drug is the first to be re-appraised form the CDF

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

- PMLiVE

inVentiv Health wins Pfizer account

Will be tasked with managing the pharma firm’s global clinical services

China drug medicine pharma prices

Pfizer earmarks $350m for first Asian biotech facility

US pharma giant looks to tap into China’s pharmaceuticals market

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links